Free Trial

West Pharmaceutical Services (WST) Stock Forecast & Price Target

West Pharmaceutical Services logo
$322.80 +0.80 (+0.25%)
As of 10:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
4
Buy
8

Based on 12 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 4 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for WST.

Consensus Price Target

$322.89
0.03% Upside
According to the 12 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $322.89. The highest price target for WST is $350.00, while the lowest price target for WST is $295.00. The average price target represents a forecasted upside of 0.03% from the current price of $322.81.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Analyst Ratings Over Time

TypeCurrent Forecast
5/8/25 to 5/8/26
1 Month Ago
4/8/25 to 4/8/26
3 Months Ago
2/7/25 to 2/7/26
1 Year Ago
5/8/24 to 5/8/25
Strong Buy
1 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$322.89$314.56$330.13$332.50
Forecasted Upside0.03% Upside18.19% Upside32.51% Upside55.11% Upside
Consensus RatingModerate BuyBuyBuyBuy

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

West Pharmaceutical Services Stock vs. The Competition

TypeWest Pharmaceutical ServicesMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside0.14% Upside841.15% Upside14.93% Upside
News Sentiment Rating
Positive News

See Recent WST News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
4/27/2026 UpgradeHold (C-)Hold (C)
4/27/2026
Morgan Stanley logo
Morgan Stanley
3 of 5 stars
 Set Target$315.00+3.84%
4/27/2026
Barclays PLC logo
Barclays
3 of 5 stars
Luke Sergott
Luke Sergott
4 of 5 stars
Boost TargetEqual Weight$275.00 ➝ $310.00+1.54%
4/24/2026 Reiterated RatingBuy
4/24/2026 Reiterated RatingOutperform
4/14/2026 DowngradeStrong-BuyHold
2/13/2026Reiterated RatingBuy$340.00+37.98%
2/13/2026Reiterated RatingBuy$315.00+29.70%
2/10/2026Reiterated RatingBuy$295.00+17.85%
10/29/2025 Initiated CoverageBuy
10/24/2025Boost TargetOverweight$325.00 ➝ $350.00+13.82%
9/15/2025Set Target$311.00+20.67%
4/21/2025UpgradeStrong-Buy
12/13/2024 Boost TargetBuy$350.00 ➝ $355.00+8.95%
12/13/2024Initiated CoveragePeer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:54 AM ET.


Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 6, 2026. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

  • The company recently reported strong earnings, with earnings per share (EPS) of $2.04, surpassing analyst expectations, which indicates robust financial health and operational efficiency.
  • West Pharmaceutical Services, Inc. has initiated a significant stock buyback program, allowing for the repurchase of up to $1 billion in shares, suggesting that management believes the stock is undervalued and is committed to enhancing shareholder value.
  • Analysts have recently upgraded their ratings on the stock, with several firms issuing "buy" ratings and raising target prices, reflecting positive sentiment and confidence in the company's growth prospects.
  • The current stock price is around $315.67, which is considered attractive given the company's strong fundamentals and growth trajectory, making it a potentially lucrative investment opportunity.
  • West Pharmaceutical Services, Inc. has demonstrated consistent revenue growth, with a year-over-year increase of 7.5%, indicating strong demand for its products in the pharmaceutical and biotech sectors.

West Pharmaceutical Services
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

  • The dividend yield is relatively low at 0.3%, which may not attract income-focused investors looking for higher returns from dividends.
  • Despite recent positive earnings, the company's net margin of 16.06% may indicate that there is limited room for further profitability improvements, which could affect future growth potential.
  • Market volatility and economic uncertainties could impact the stock price, making it a riskier investment in the current climate.
  • While the stock buyback program is a positive signal, it may also indicate that the company lacks alternative growth opportunities, which could limit long-term expansion.
  • Analyst ratings can be subject to change, and the current positive sentiment may not be sustainable if the company faces unexpected challenges in the market.

WST Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $322.89, with a high forecast of $350.00 and a low forecast of $295.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 4 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WST shares.

According to analysts, West Pharmaceutical Services's stock has a predicted upside of 0.03% based on their 12-month stock forecasts.

Over the previous 90 days, West Pharmaceutical Services's stock had 1 upgrade and 1 downgrade by analysts.

West Pharmaceutical Services has been rated by research analysts at Barclays, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore, Jefferies Financial Group, Morgan Stanley, UBS Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like West Pharmaceutical Services more than other "medical" companies. The consensus rating for West Pharmaceutical Services is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how WST compares to other companies.


This page (NYSE:WST) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners